These patients receive conventional chemotherapy or immunotherapy, often with limited efficacy and potential toxicity4,6,7 except for KRAS-mutant NSCLC patients who benefit from immune check-point inhibitors compared with KRAS wild-type patients.8 Here, KRAS is linked to non-small cell lung carcinoma.